JAMA Network Home
Sign In
Viewpoint

Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US

JAMA Oncology 10.1001/jamaoncol.2026.2843

August 20, 2026 at 11:00 AM EDT

Read the full article

This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.

Corresponding Author: Gilberto Lopes, MD, MBA, Sylvester Comprehensive Cancer Center at the University of Miami, 1120 NW 14th St, Miami, FL 33136 (glopes.md@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.2843?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks